2021
DOI: 10.21203/rs.3.rs-1032345/v1
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Soluble Amyloid-Beta Isoforms Predict Downstream Alzheimer’s Disease Pathology

Abstract: Background: Changes in soluble amyloid-beta (Aβ) levels in cerebrospinal fluid (CSF) are detectable at early preclinical stages of Alzheimer's disease (AD). However, whether Aβ levels can predict downstream AD pathological features in cognitively unimpaired (CU) individuals remains unclear. With this in mind, we aimed at investigating whether a combination of soluble Aβ isoforms can predict tau pathology (T+) and neurodegeneration (N+) positivity. Methods: We used CSF measurements of three soluble Aβ peptides … Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 39 publications
0
1
0
Order By: Relevance
“…However, many of these tau probes have yet to be evaluated in biologically relevant samples such as brain tissue or biological fluids such as cerebrospinal fluid (CSF). Elevated levels of soluble aggregates of amyloidogenic proteins in CSF have been reported in patients with AD, therefore the detection of endogenous levels of these aggregates in CSF may complement AD diagnosis as a less invasive avenue that can potentially allow for monitoring of AD progression (Blennow, 2004;De et al, 2019;Povala et al, 2021). The design of fluorescent probes that can detect oligomeric α-Synuclein are currently based on scaffolds that showed promise as a probe for detecting Lewy bodies and neurites and have been limited to experiments in vitro.…”
Section: Discussionmentioning
confidence: 99%
“…However, many of these tau probes have yet to be evaluated in biologically relevant samples such as brain tissue or biological fluids such as cerebrospinal fluid (CSF). Elevated levels of soluble aggregates of amyloidogenic proteins in CSF have been reported in patients with AD, therefore the detection of endogenous levels of these aggregates in CSF may complement AD diagnosis as a less invasive avenue that can potentially allow for monitoring of AD progression (Blennow, 2004;De et al, 2019;Povala et al, 2021). The design of fluorescent probes that can detect oligomeric α-Synuclein are currently based on scaffolds that showed promise as a probe for detecting Lewy bodies and neurites and have been limited to experiments in vitro.…”
Section: Discussionmentioning
confidence: 99%